The beta-2 adrenergic receptor and its agonists

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The β2 adrenoceptor has been cloned and sequenced, and details of how agonist stimulation ultimately results in clinically evident effects are now known. Receptor desensitization by agonist is an almost universal process that can be prevented and reversed by corticosteroids. Although immunologic mechanisms appear to prevail in asthma, β2 receptor dysfunction may be important in some circumstances. Many receptor agonists are available for asthma therapy, including a new generation of long acting agents (such as salmeterol) with duration of action of 12 hours or more. Statistical links between beta agonist use and asthma mortality or morbidity warrant careful examination for clinical relevance, but may not be dismissed. Beta agonists are relatively safe and clearly effective in asthma, but anti-inflammatory management (including allergen avoidance and immunotherapy when appropriate) is indicated in patients who require chronic therapy.

Original languageEnglish (US)
Pages (from-to)283-290
Number of pages8
JournalAllergy Proceedings
Volume15
Issue number6
StatePublished - Dec 1 1994

Fingerprint

Adrenergic beta-2 Receptor Agonists
Asthma
Immunologic Desensitization
Adrenergic Receptors
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Morbidity
Mortality
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

The beta-2 adrenergic receptor and its agonists. / Dolen, W. K.

In: Allergy Proceedings, Vol. 15, No. 6, 01.12.1994, p. 283-290.

Research output: Contribution to journalReview article

@article{a13f94b3b2a24faaaabf7ec71d09d19a,
title = "The beta-2 adrenergic receptor and its agonists",
abstract = "The β2 adrenoceptor has been cloned and sequenced, and details of how agonist stimulation ultimately results in clinically evident effects are now known. Receptor desensitization by agonist is an almost universal process that can be prevented and reversed by corticosteroids. Although immunologic mechanisms appear to prevail in asthma, β2 receptor dysfunction may be important in some circumstances. Many receptor agonists are available for asthma therapy, including a new generation of long acting agents (such as salmeterol) with duration of action of 12 hours or more. Statistical links between beta agonist use and asthma mortality or morbidity warrant careful examination for clinical relevance, but may not be dismissed. Beta agonists are relatively safe and clearly effective in asthma, but anti-inflammatory management (including allergen avoidance and immunotherapy when appropriate) is indicated in patients who require chronic therapy.",
author = "Dolen, {W. K.}",
year = "1994",
month = "12",
day = "1",
language = "English (US)",
volume = "15",
pages = "283--290",
journal = "Allergy and Asthma Proceedings",
issn = "1088-5412",
publisher = "OceanSide Publications Inc.",
number = "6",

}

TY - JOUR

T1 - The beta-2 adrenergic receptor and its agonists

AU - Dolen, W. K.

PY - 1994/12/1

Y1 - 1994/12/1

N2 - The β2 adrenoceptor has been cloned and sequenced, and details of how agonist stimulation ultimately results in clinically evident effects are now known. Receptor desensitization by agonist is an almost universal process that can be prevented and reversed by corticosteroids. Although immunologic mechanisms appear to prevail in asthma, β2 receptor dysfunction may be important in some circumstances. Many receptor agonists are available for asthma therapy, including a new generation of long acting agents (such as salmeterol) with duration of action of 12 hours or more. Statistical links between beta agonist use and asthma mortality or morbidity warrant careful examination for clinical relevance, but may not be dismissed. Beta agonists are relatively safe and clearly effective in asthma, but anti-inflammatory management (including allergen avoidance and immunotherapy when appropriate) is indicated in patients who require chronic therapy.

AB - The β2 adrenoceptor has been cloned and sequenced, and details of how agonist stimulation ultimately results in clinically evident effects are now known. Receptor desensitization by agonist is an almost universal process that can be prevented and reversed by corticosteroids. Although immunologic mechanisms appear to prevail in asthma, β2 receptor dysfunction may be important in some circumstances. Many receptor agonists are available for asthma therapy, including a new generation of long acting agents (such as salmeterol) with duration of action of 12 hours or more. Statistical links between beta agonist use and asthma mortality or morbidity warrant careful examination for clinical relevance, but may not be dismissed. Beta agonists are relatively safe and clearly effective in asthma, but anti-inflammatory management (including allergen avoidance and immunotherapy when appropriate) is indicated in patients who require chronic therapy.

UR - http://www.scopus.com/inward/record.url?scp=0028594056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028594056&partnerID=8YFLogxK

M3 - Review article

VL - 15

SP - 283

EP - 290

JO - Allergy and Asthma Proceedings

JF - Allergy and Asthma Proceedings

SN - 1088-5412

IS - 6

ER -